Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Andrej Bešše"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Chemotherapy resistance is still a major problem in the treatment of patients with non-small-cell-lung carcinoma (NSCLC), and novel concepts for the induction of cytotoxicity in NSCLC are highly warranted. Proteotoxicity, the induction of cy
Externí odkaz:
https://doaj.org/article/cec06593dd9b473585e814bdc048f845
Autor:
Xiang Zhou, Andrej Besse, Jessica Peter, Maximilian Johannes Steinhardt, Cornelia Vogt, Silvia Nerreter, Eva Teufel, Emilia Stanojkovska, Xianghui Xiao, Hannah Hornburger, Larissa Haertle, Max Mendez Lopez, Umair Munawar, Angela Riedel, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Bogdan Florea, Hermann Einsele, K. Martin Kortüm, Christoph Driessen, Lenka Besse, Leo Rasche
Publikováno v:
Haematologica, Vol 108, Iss 6 (2023)
Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27 mg/m2) versus high-dose (≥36 mg/m2) carfilzomib in 103 pairs of peripheral blood mononuc
Externí odkaz:
https://doaj.org/article/145781d6796c4523aa127a2cf8216c97
Autor:
Johannes Kliebhan, Andrej Besse, Kerstin Kampa‐Schittenhelm, Marcus Schittenhelm, Christoph Driessen
Publikováno v:
Clinical Case Reports, Vol 10, Iss 10, Pp n/a-n/a (2022)
Abstract The p53 mutation R273H in tumor cells leads to increased glucose uptake, lactic acidosis, and accelerated tumor growth, as was previously shown in mice. We here present a patient with mantle cell lymphoma harboring this p53_R273H mutation, w
Externí odkaz:
https://doaj.org/article/fbf970e3ed7542df998e4ada31dee0af
Autor:
Sandra S. Ring, Jovana Cupovic, Lucas Onder, Mechthild Lütge, Christian Perez-Shibayama, Cristina Gil-Cruz, Elke Scandella, Angelina De Martin, Urs Mörbe, Fabienne Hartmann, Robert Wenger, Matthias Spiegl, Andrej Besse, Weldy V. Bonilla, Felix Stemeseder, Sarah Schmidt, Klaus K. Orlinger, Philippe Krebs, Burkhard Ludewig, Lukas Flatz
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Lymphocytic choriomeningitis virus (LCMV)-based viral vectors have been shown to induce potent antitumor immune responses. Here the authors show that a LCMV-based vaccine vector remodels the tumor-associated fibroblastic stroma, sustaining CD8+ T cel
Externí odkaz:
https://doaj.org/article/6b57b0ebdd6c41a2b423f124d18a7987
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Virtually all patients with multiple myeloma become unresponsive to treatment with proteasome inhibitors over time. Relapsed/refractory multiple myeloma is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations, d
Externí odkaz:
https://doaj.org/article/8df91ec352b34787ac56a4eb20d2143d
Autor:
Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Besse
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e602 (2021)
Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to bortezom
Externí odkaz:
https://doaj.org/article/5b74bd320c2440168f319eecd0ee0e6a
Autor:
Andrej Besse, Marianne Kraus, Max Mendez-Lopez, Elmer Maurits, Herman S. Overkleeft, Christoph Driessen, Lenka Besse
Publikováno v:
Cells, Vol 11, Iss 5, p 838 (2022)
Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target both the constitutive a
Externí odkaz:
https://doaj.org/article/c3eb49a99057448a92068364293fc7f7
Autor:
Jiri Sana, Petr Busek, Pavel Fadrus, Andrej Besse, Lenka Radova, Marek Vecera, Stefan Reguli, Lucie Stollinova Sromova, Marek Hilser, Radim Lipina, Radek Lakomy, Leos Kren, Martin Smrcka, Aleksi Sedo, Ondrej Slaby
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Glioblastoma stem-like cells (GSCs) are critical for the aggressiveness and progression of glioblastoma (GBM) and contribute to its resistance to adjuvant treatment. MicroRNAs (miRNAs) are small, non-coding RNAs controlling gene expression a
Externí odkaz:
https://doaj.org/article/45af015b41e7425cbe979cb802a41555
Autor:
Lenka Besse, Andrej Besse, Marianne Kraus, Elmer Maurits, Herman S. Overkleeft, Beat Bornhauser, Jean-Pierre Bourquin, Christoph Driessen
Publikováno v:
Cells, Vol 10, Iss 11, p 2853 (2021)
Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic leu
Externí odkaz:
https://doaj.org/article/3cf2946c3b5a4867896f938449af3ded
Autor:
Lenka Besse, Andrej Besse, Max Mendez-Lopez, Katerina Vasickova, Miroslava Sedlackova, Petr Vanhara, Marianne Kraus, Jürgen Bader, Renan B. Ferreira, Ronald K. Castellano, Brian K. Law, Christoph Driessen
Publikováno v:
Haematologica, Vol 104, Iss 9 (2019)
Externí odkaz:
https://doaj.org/article/783f077c27e6451a976c2a746087d637